This site is intended for healthcare professionals

Lantheus receives FDA approval of Pylarify injection, the first and only commercially available PSMA PET imaging agent for prostate cancer.

Read time: 1 mins
Last updated:1st Jun 2021
Published:30th May 2021
Lantheus Holdings, Inc. announced that the FDA has approved Pylarify, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent to identify suspected metastasis or recurrence of prostate cancer.
Condition: Imaging:PET
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest